- Home
- SLDP vs LYEL Comparison
SLDP vs LYEL Comparison
Compare SLDP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLDP | LYEL |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 876.8M | 745.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLDP | LYEL |
|---|---|---|
| Price | $4.64 | $28.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 6.4M | 122.2K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,802,000.00 | $41,000.00 |
| Revenue This Year | $27.38 | N/A |
| Revenue Next Year | $36.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.85 | N/A |
| 52 Week Low | $0.68 | $7.65 |
| 52 Week High | $8.86 | $45.00 |
Technical Indicators
Market Signals| Indicator | SLDP | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 47.84 |
| Support Level | $4.14 | $32.01 |
| Resistance Level | $4.67 | $45.00 |
| Average True Range (ATR) | 0.29 | 3.47 |
| MACD | 0.01 | -0.96 |
| Stochastic Oscillator | 44.39 | 9.62 |
Price Performance
Historical ComparisonAbout SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.